Mitesh J Borad1, Shantan G Reddy2, Nathan Bahary2, Hope E Uronis2, Darren Sigal2, Allen L Cohn2, William R Schelman2, Joe Stephenson2, E Gabriela Chiorean2, Peter J Rosen2, Brian Ulrich2, Tomislav Dragovich2, Salvatore A Del Prete2, Mark Rarick2, Clarence Eng2, Stew Kroll2, David P Ryan2. 1. Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA. Borad.mitesh@mayo.edu. 2. Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.
Abstract
PURPOSE: TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. PATIENTS AND METHODS: Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m(2)), gemcitabine plus TH-302 240 mg/m(2) (G+T240), or gemcitabine plus TH-302 340 mg/m(2) (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), tumor response, CA 19-9 response, and safety. RESULTS:Two hundred fourteen patients (77% with metastatic disease) were enrolled between June 2010 and July 2011. PFS was significantly longer with gemcitabine plus TH-302 (pooled combination arms) compared with gemcitabine alone (median PFS, 5.6 v 3.6 months, respectively; hazard ratio, 0.61; 95% CI, 0.43 to 0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, respectively). Median PFS times for G+T240 and G+T340 were 5.6 and 6.0 months, respectively. Tumor response was 12%, 17%, and 26% in the gemcitabine, G+T240, and G+T340 arms, respectively (G+T340 v gemcitabine, P = .04). CA 19-9 decrease was greater with G+T340 versus gemcitabine (-5,398 v -549 U/mL, respectively; P = .008). Median OS times for gemcitabine, G+T240, and G+T340 were 6.9, 8.7, and 9.2 months, respectively (P = not significant). The most common adverse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms). Skin and mucosal toxicities (2% grade 3) and myelosuppression (55% grade 3 or 4) were the most common TH-302-related AEs but were not associated with treatment discontinuation. CONCLUSION:PFS, tumor response, and CA 19-9 response were significantly improved with G+TH-302. G+T340 is being investigated further in the phase III MAESTRO study (NCT01746979).
RCT Entities:
PURPOSE:TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer. PATIENTS AND METHODS: Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m(2)), gemcitabine plus TH-302 240 mg/m(2) (G+T240), or gemcitabine plus TH-302 340 mg/m(2) (G+T340). Randomized crossover after progression on gemcitabine was allowed. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), tumor response, CA 19-9 response, and safety. RESULTS: Two hundred fourteen patients (77% with metastatic disease) were enrolled between June 2010 and July 2011. PFS was significantly longer with gemcitabine plus TH-302 (pooled combination arms) compared with gemcitabine alone (median PFS, 5.6 v 3.6 months, respectively; hazard ratio, 0.61; 95% CI, 0.43 to 0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, respectively). Median PFS times for G+T240 and G+T340 were 5.6 and 6.0 months, respectively. Tumor response was 12%, 17%, and 26% in the gemcitabine, G+T240, and G+T340 arms, respectively (G+T340 v gemcitabine, P = .04). CA 19-9 decrease was greater with G+T340 versus gemcitabine (-5,398 v -549 U/mL, respectively; P = .008). Median OS times for gemcitabine, G+T240, and G+T340 were 6.9, 8.7, and 9.2 months, respectively (P = not significant). The most common adverse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across arms). Skin and mucosal toxicities (2% grade 3) and myelosuppression (55% grade 3 or 4) were the most common TH-302-related AEs but were not associated with treatment discontinuation. CONCLUSION: PFS, tumor response, and CA 19-9 response were significantly improved with G+TH-302. G+T340 is being investigated further in the phase III MAESTRO study (NCT01746979).
Authors: Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart Journal: Cancer Chemother Pharmacol Date: 2012-03-02 Impact factor: 3.333
Authors: Limin Chen; Zhengwei Zhang; Hartmuth C Kolb; Joseph C Walsh; James Zhang; Yihui Guan Journal: Nucl Med Commun Date: 2012-10 Impact factor: 1.690
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Jian-Xin Duan; Hailong Jiao; Jacob Kaizerman; Timothy Stanton; James W Evans; Leslie Lan; Gustavo Lorente; Monica Banica; Don Jung; Jinwei Wang; Huaiyu Ma; Xiaoming Li; Zhijian Yang; Robert M Hoffman; W Steve Ammons; Charles P Hart; Mark Matteucci Journal: J Med Chem Date: 2008-02-08 Impact factor: 7.446
Authors: Xinjian Mao; Sarah McManaway; Jagdish K Jaiswal; Cho R Hong; William R Wilson; Kevin O Hicks Journal: Cancer Biol Ther Date: 2019-05-26 Impact factor: 4.742
Authors: Talha Badar; Damian R Handisides; Juliana M Benito; Mary Ann Richie; Gautam Borthakur; Elias Jabbour; Karine Harutyunyan; Sergej Konoplev; Stefan Faderl; Stew Kroll; Michael Andreeff; Tillman Pearce; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Marina Konopleva Journal: Am J Hematol Date: 2016-06-25 Impact factor: 10.047
Authors: Stephen Mf Jamieson; Peter Tsai; Maria K Kondratyev; Pratha Budhani; Arthur Liu; Neil N Senzer; E Gabriela Chiorean; Shadia I Jalal; John J Nemunaitis; Dennis Kee; Avik Shome; Way W Wong; Dan Li; Nooriyah Poonawala-Lohani; Purvi M Kakadia; Nicholas S Knowlton; Courtney Rh Lynch; Cho R Hong; Tet Woo Lee; Reidar A Grénman; Laura Caporiccio; Trevor D McKee; Mark Zaidi; Sehrish Butt; Andrew Mj Macann; Nicholas P McIvor; John M Chaplin; Kevin O Hicks; Stefan K Bohlander; Bradly G Wouters; Charles P Hart; Cristin G Print; William R Wilson; Michael A Curran; Francis W Hunter Journal: JCI Insight Date: 2018-08-23
Authors: Jean-Luc Van Laethem; Hanno Riess; Jacek Jassem; Michael Haas; Uwe M Martens; Colin Weekes; Marc Peeters; Paul Ross; John Bridgewater; Bohuslav Melichar; Stefano Cascinu; Piotr Saramak; Patrick Michl; David Van Brummelen; Alberto Zaniboni; Wollf Schmiegel; Svein Dueland; Marius Giurescu; Vittorio L Garosi; Katrin Roth; Anke Schulz; Henrik Seidel; Prabhu Rajagopalan; Michael Teufel; Barrett H Childs Journal: Target Oncol Date: 2017-02 Impact factor: 4.493
Authors: Shingo Matsumoto; Shun Kishimoto; Keita Saito; Yoichi Takakusagi; Jeeva P Munasinghe; Nallathamby Devasahayam; Charles P Hart; Robert J Gillies; James B Mitchell; Murali C Krishna Journal: Cancer Res Date: 2018-05-23 Impact factor: 12.701
Authors: Jessica D Sun; Dharmendra Ahluwalia; Qian Liu; Wenwu Li; Yan Wang; Fanying Meng; Deepthi Bhupathi; Mark D Matteucci; Charles P Hart Journal: Am J Cancer Res Date: 2015-06-15 Impact factor: 6.166